Sanofi, Alnylam’s RNAi therapeutic smashes PhIII targets
An investigational RNAi therapeutic being developed by Sanofi Genzyme and Alnylam Pharmaceuticals has hit targets in a late stage trial involving patients with hereditary ATTR amyloidosis with polyneuropathy.
Read More
